Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study

INTRODUCTION: The TIGER-3 (NCT02322281) study was initiated to compare the efficacy and safety of rociletinib, a third-generation EGFR tyrosine kinase inhibitor (TKI) that targets EGFR T790M and common EGFR-activating mutations, versus chemotherapy in patients with NSCLC who progressed on first- or...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, James Chih-Hsin, Reckamp, Karen L., Kim, Young-Chul, Novello, Silvia, Smit, Egbert F., Lee, Jong-Seok, Su, Wu-Chou, Akerley, Wallace L., Blakely, Collin M., Groen, Harry J.M., Bazhenova, Lyudmila, Carcereny Costa, Enric, Chiari, Rita, Hsia, Te-Chun, Golsorkhi, Tony, Despain, Darrin, Shih, Danny, Popat, Sanjay, Wakelee, Heather
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474221/
https://www.ncbi.nlm.nih.gov/pubmed/34589984
http://dx.doi.org/10.1016/j.jtocrr.2020.100114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474221/
https://www.ncbi.nlm.nih.gov/pubmed/34589984
http://dx.doi.org/10.1016/j.jtocrr.2020.100114

Ejemplares similares